Chemodex

Prostaglandin E2

CHF 81.00
In stock
CDX-P0318-M0055 mgCHF 81.00
CDX-P0318-M01010 mgCHF 122.00
CDX-P0318-M02525 mgCHF 244.00
More Information
Product Details
Synonyms Dinoprostone; ((5Z,11a,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid; PGE2
Product Type Chemical
Properties
Formula

C20H32O5

MW 352.47
CAS 363-24-6
RTECS UK8000000
Source/Host Chemicals Synthetic
Purity Chemicals ≥98% (HPLC)
Appearance White to light yellow solid.
Solubility Soluble in ethanol (50 mg/ml), DMSO (50 mg/ml) or DMF (100 mg/ml). Sparingly soluble in PBS, pH 7.2 (5mg/ml).
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key XEYBRNLFEZDVAW-ARSRFYASSA-N
Smiles O=C1C[C@@H](O)[C@H](/C=C/[C@@H](O)CCCCC)[C@H]1C/C=C\CCCC(O)=O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

Prostaglandin E2 is one of the most typical lipid mediators produced from arachidonic acid (AA) by cyclooxygenase (COX) as the rate-limiting enzyme and acts on four kinds of receptor subtypes (EP1, EP2, EP3 and EP4) with high binding affinity. It is a regulator of numerous physiological functions ranging from reproduction to neuronal, metabolic and immune functions. It acts as a pro-inflammatory mediator, but also exerts anti-inflammatory responses. As pro-inflammatory mediator, PGE2 contributes to the regulation of the cytokine expression profile of DCs and has been reported to bias T cell differentiation towards a T helper (Th) 1 or Th2 response. It exerts anti-inflammatory actions on innate immune cells like neutrophils, monocytes and NK cells. Prostaglandin E2 also facilitates tumor progression through stimulation of angiogenesis via EP2, mediates cell invasion and metastasis formation via EP4 and promotes cell survival by inhibiting apoptosis via numerous signaling pathways. Recently it has been shown to inhibit NLRP3 by acting through receptor EP4 activation that increases cAMP. cAMP activates PKA that phosphorylates NLRP3 at serine 295. PKA phosphorylation of NLRP3 inhibits the NLRP3 ATPase activity, which is required for assembly of NLRP3-ASC complexes.

Product References

(1) D. F. Legler, et al.; Int. J. Biochem. Cell Biol. 42, 198 (2010) (Review) | (2) D. Sakata, et al.; J. Pharmacol. Sci. 112, 1 (2010) (Review) | (3) E.M. Durand, et al.; Curr. Opin. Hematol. 17, 308 (2010) (Review) | (4) J. Reader, et al.; Cancer Metastasis Rev. 30, 449 (2011) (Review) | (5) V. Sreeramkumar, et al.; Immunol. Cell Biol. 90, 579 (2012) (Review) | (6) P. Kalinski; J. Immunol. 188, 21 (2012) (Review) | (7) M. Rodriguez, et al.; Mol. Pharmacol. 85, 187 (2014) (Review) | (8) K. Kawahara, et al.; Biochim. Biophys Acta. 1851, 414 (2015) (Review) | (9) M. Sokolowska, et al.; J. Immunol. 194, 5472 (2015)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.